Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovista, a biotechnology company, has received $0.5m grant, for research and development in the area of personalized medicine.
Subscribe to our email newsletter
Biovista expects to utilize its Clinical Outcomes Search Space (COSS) platform and multi-dimensional profiling capabilities to identify new treatments that reflect patients’ individual pathophysiological characteristics.
The ‘p-medicine’ project is a four-year, EUR13.3m co-funded effort under the European Community’s 7th Framework Program that aims to develop new tools, infrastructure and VPH (Virtual Physiological Human) models in order to help accelerate the emergence of personalized medicine.
Biovista CEO Andreas Persidis said they are confident that their drug repositioning expertise combined with clinical and related data that will be easily integrated and interchangeable via the p-medicine infrastructure can move us in the right direction.